[go: up one dir, main page]

CY1111357T1 - Τυποποιησεις αποθεματος ιλοπεριδονης και πολυμερους αστερα - Google Patents

Τυποποιησεις αποθεματος ιλοπεριδονης και πολυμερους αστερα

Info

Publication number
CY1111357T1
CY1111357T1 CY20111100327T CY111100327T CY1111357T1 CY 1111357 T1 CY1111357 T1 CY 1111357T1 CY 20111100327 T CY20111100327 T CY 20111100327T CY 111100327 T CY111100327 T CY 111100327T CY 1111357 T1 CY1111357 T1 CY 1111357T1
Authority
CY
Cyprus
Prior art keywords
standards
heloperidon
star
stock
polymer
Prior art date
Application number
CY20111100327T
Other languages
English (en)
Inventor
Markus Ahlheim
Rolf Löffler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1111357T1 publication Critical patent/CY1111357T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Αυτή η παρούσα εφεύρεση αναφέρεται σε φαρμακευτικές συνθέσεις, συγκεκριμένα σε τυποποιήσεις αποθέματος οι οποίες περιέχουν ιλοπεριδόνη ως δραστικό μέσον και ένα βιοαποδομήσιμο, βιοσυμβατό πολυμερές, καθώς και σε διαδικασία για την παρασκευή τυποποιήσεων αποθέματος μικροσωματιδίων.
CY20111100327T 2001-10-30 2011-03-28 Τυποποιησεις αποθεματος ιλοπεριδονης και πολυμερους αστερα CY1111357T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33903601P 2001-10-30 2001-10-30
EP02785330A EP1441727B1 (en) 2001-10-30 2002-10-29 Depot formulations of iloperidone and a star polymer

Publications (1)

Publication Number Publication Date
CY1111357T1 true CY1111357T1 (el) 2015-08-05

Family

ID=23327202

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100327T CY1111357T1 (el) 2001-10-30 2011-03-28 Τυποποιησεις αποθεματος ιλοπεριδονης και πολυμερους αστερα

Country Status (12)

Country Link
US (2) US7767230B2 (el)
EP (2) EP2295058B1 (el)
JP (1) JP5067998B2 (el)
CN (2) CN1578664A (el)
AT (1) ATE493129T1 (el)
BR (1) BRPI0213564B8 (el)
CA (1) CA2463158C (el)
CY (1) CY1111357T1 (el)
DE (1) DE60238780D1 (el)
ES (2) ES2358416T3 (el)
HK (2) HK1068263A1 (el)
WO (1) WO2003037337A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148372A0 (en) * 1999-09-09 2002-09-12 Univ California Cationic liposome delivery of taxanes to angiogenic blood vessels
EP2295058B1 (en) * 2001-10-30 2013-09-04 Novartis AG Depot formulations of iloperidone with a polymer
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
EP2479290B1 (en) 2004-09-30 2020-08-19 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
JP5264492B2 (ja) 2005-10-25 2013-08-14 エボニック デグサ ゲーエムベーハー 超分岐ポリマーを含有する調製物
DE102005051342A1 (de) * 2005-10-25 2007-04-26 Goldschmidt Gmbh Verkapselung und kontrollierte Freisetzung biologisch aktiver Wirkstoffe mit enzymatisch abbaubaren hyperverzweigten Trägerpolymeren
JP2009538331A (ja) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
CN100460441C (zh) * 2006-09-25 2009-02-11 南开大学 生物可降解星型结构聚乙丙交酯载药微球及其制备方法
EP2078052B1 (en) 2006-10-31 2010-07-28 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
US8652776B2 (en) * 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
ES2527515T3 (es) * 2007-12-13 2015-01-26 Vanda Pharmaceuticals Inc. Método y composición para tratar una afección mediada por un adrenoceptor alfa
PT2222300E (pt) 2007-12-13 2014-07-28 Vanda Pharmaceuticals Inc Método e composição para tratamento de uma condição mediada por recetores da serotonina
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
MX2012007365A (es) * 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
CN102311430A (zh) * 2010-06-29 2012-01-11 大道隆达（北京）医药科技发展有限公司 伊潘立酮的新晶态及其制备方法
WO2012123963A2 (en) * 2011-02-24 2012-09-20 Megafine Pharma (P) Ltd. A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112949A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA2872324C (en) 2012-05-18 2017-06-06 Vanda Pharmaceuticals Inc. Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
MX377667B (es) 2012-12-18 2025-03-11 Vanda Pharmaceuticals Inc Uso de un agonista de malatonina para el tratamiento de ritmos circadianos de curso libre.
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
CN104352443A (zh) * 2014-10-21 2015-02-18 河北科技大学 伊潘立酮缓释微球及其制备方法
CA2976383C (en) 2015-02-17 2023-05-23 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
EP3890705A1 (en) * 2018-12-04 2021-10-13 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3511587A1 (de) 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
DE69021645T2 (de) * 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HUT63185A (en) 1990-06-04 1993-07-28 Schering Corp Process for producing crystalline alpha-2-interferon
HU219487B (hu) * 1993-11-19 2001-04-28 Janssen Pharmaceutica Nv. Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
BR9809162A (pt) 1997-05-26 2000-08-01 Akzo Nobel Nv Sal de trans-5-cloro-2, 3, 3a, 12b-tetrahidro-2-metil-1h-dibenz [2,3:6,7] oxepino[4,5-c] pirrol e agente formador de sal, composto, composição farmacêutica, e, preparação de injeção armazenável
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
ID28441A (id) * 1998-10-16 2001-05-24 Janssen Pharmaceutica Nv Terapi untuk memperbaiki kesadaran
EP1290024A1 (en) 2000-06-02 2003-03-12 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
EP1425272B1 (en) 2001-08-31 2011-08-03 Novartis AG Optical isomers of an iloperidone metabolite
EP2295058B1 (en) * 2001-10-30 2013-09-04 Novartis AG Depot formulations of iloperidone with a polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HK1155381A1 (en) 2012-05-18
ES2436439T3 (es) 2014-01-02
JP5067998B2 (ja) 2012-11-07
CA2463158C (en) 2013-07-30
WO2003037337A8 (en) 2004-05-13
DE60238780D1 (de) 2011-02-10
BR0213564A (pt) 2004-08-31
ATE493129T1 (de) 2011-01-15
CA2463158A1 (en) 2003-05-08
CN1578664A (zh) 2005-02-09
US20030091645A1 (en) 2003-05-15
ES2358416T3 (es) 2011-05-10
US7767230B2 (en) 2010-08-03
EP1441727B1 (en) 2010-12-29
WO2003037337A1 (en) 2003-05-08
EP2295058A1 (en) 2011-03-16
JP2005508975A (ja) 2005-04-07
BRPI0213564B8 (pt) 2021-05-25
HK1068263A1 (en) 2005-04-29
US20100233217A1 (en) 2010-09-16
BRPI0213564B1 (pt) 2016-08-02
EP2295058B1 (en) 2013-09-04
EP1441727A1 (en) 2004-08-04
US8815293B2 (en) 2014-08-26
CN101912367A (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
CY1111357T1 (el) Τυποποιησεις αποθεματος ιλοπεριδονης και πολυμερους αστερα
ATE236218T1 (de) Ethylenpolymerzusammensetzungen und daraus hergestellte gegenstände
DE69728307D1 (de) Absorbierbare polymer Mischungen und chirurgische Gegenstände daraus
NO984923D0 (no) Sure polymelkesyrepolymerer
ATE336029T1 (de) Lichtempfindliche zusammensetzung und 1,3-dihydro-1-oxo-2h-indenderivat
DE60144375D1 (de) 7-, 8- und 9-substitutierte tetracyclinverbindungen
PT831097E (pt) Di-hidrato d de olanzapina
CY1108348T1 (el) Υποκατεστημενα 2-(2,6-διοξοπιπεριδιν-3-υλ)-φθαλιμιδια και μεθοδος μειωσης των tnf αλφα επιπεδων
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE291532T1 (de) Mehrschichtige etiketthülse
ATE267145T1 (de) Mikronisiertes bariumsulfat
WO2002101007A3 (en) Antipathogenic benzamide compounds
BR9905881B1 (pt) composição de resina e processo para a preparação de composições de resina de tereftalato de polietileno-isoftalato de polietileno.
DE69902913D1 (de) Injizierbare zweiphasige zusammensetzungen für kosmetische und plastische chirurgie
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
BR9400436A (pt) Polímero, sutura e artigo cirúrgico
ATE339896T1 (de) Biologisch abbaubare kaugummigrundmasse
BR9707527A (pt) Composicões de inseticidas á base de polímeros
DE69132415D1 (de) Umweltfreundliche Polymerzusammensetzungen sowie Anwendungen desselben
EP1053000A4 (en) AGENTS AND METHODS FOR PROTECTING, TREATING AND REPAIRING CONNECTIVE TISSUE
DE69901023D1 (de) Knochenimplantat
DE69418114D1 (de) Biodegradierbare Harzzusammensetzung und fäulnisverhindernde Lackzusammensetzung
ATE304033T1 (de) Pvc-haltiges material
NO991881D0 (no) Peroksidholdige blandinger for herding av polymerer
FR2790761B1 (fr) Copolyester aliphatique biodegradable et son procede d'obtention